

Jiri Horacek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7235756/publications.pdf>

Version: 2024-02-01

76
papers

2,790
citations

218381

26
h-index

197535

49
g-index

77
all docs

77
docs citations

77
times ranked

4295
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of a Long Lockdown on Mental Health and the Role of Media Use: Web-Based Survey Study. JMIR Mental Health, 2022, 9, e36050.	1.7	1
2	Psilocybin-Mediated Attenuation of Gamma Band Auditory Steady-State Responses (ASSR) Is Driven by the Intensity of Cognitive and Emotional Domains of Psychedelic Experience. Journal of Personalized Medicine, 2022, 12, 1004.	1.1	3
3	Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?. Frontiers in Psychiatry, 2021, 12, 661233.	1.3	41
4	Is short-term memory capacity (7 ± 2) really predicted by theta to gamma cycle length ratio?. Behavioural Brain Research, 2021, 414, 113465.	1.2	5
5	Global Adversities, the Media, and Mental Health. Frontiers in Psychiatry, 2021, 12, 809239.	1.3	3
6	The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action. Frontiers in Pharmacology, 2020, 11, 602590.	1.6	11
7	The Role of Zebrafish and Laboratory Rodents in Schizophrenia Research. Frontiers in Psychiatry, 2020, 11, 703.	1.3	24
8	The Antidepressant Effect of Ketamine Is Dampened by Concomitant Benzodiazepine Medication. Frontiers in Psychiatry, 2020, 11, 844.	1.3	29
9	Functional Connectivity Changes in Obsessive-Compulsive Disorder Correspond to Interference Control and Obsessions Severity. Frontiers in Neurology, 2020, 11, 568.	1.1	8
10	Effects of adipokinetic hormone/red pigment-concentrating hormone family of peptides in olfactory bulbectomy model and posttraumatic stress disorder model of rats. Peptides, 2020, 134, 170408.	1.2	2
11	Three challenges that the COVID-19 pandemic represents for psychiatry. British Journal of Psychiatry, 2020, 217, 475-476.	1.7	19
12	Augmentation therapy of N-acetylcysteine for OCD: A meta-analysis of double-blind, randomized, placebo-controlled trials. Journal of Obsessive-Compulsive and Related Disorders, 2019, 23, 100481.	0.7	0
13	The effect of gabapentin and pregabalin on bone turnover and bone strength: A prospective study in Wistar rats. Pharmacological Reports, 2019, 71, 1213-1218.	1.5	6
14	Intrinsic Rivalry. Can White Bears Help Us With the Other Side of Consciousness?. Frontiers in Psychology, 2019, 10, 1087.	1.1	2
15	Cannabis-induced altered states of consciousness are associated with specific dynamic brain connectivity states. Journal of Psychopharmacology, 2019, 33, 811-821.	2.0	15
16	Neural and neuronal discoordination in schizophrenia: From ensembles through networks to symptoms. Acta Physiologica, 2019, 226, e13282.	1.8	21
17	Negative Effects of Latent Toxoplasmosis on Mental Health. Frontiers in Psychiatry, 2019, 10, 1012.	1.3	40
18	Toxoplasmosis, but not borreliosis, is associated with psychiatric disorders and symptoms. Schizophrenia Research, 2018, 197, 603-604.	1.1	32

#	ARTICLE	IF	CITATIONS
19	Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing – study on P300 and mismatch negativity in healthy volunteers. <i>Psychopharmacology</i> , 2018, 235, 491-503.	1.5	26
20	Role of Glutamatergic System in Obsessive-Compulsive Disorder with Possible Therapeutic Implications. <i>Pharmacopsychiatry</i> , 2018, 51, 229-242.	1.7	23
21	EEG coherence in a mental arithmetic task performance in first episode schizophrenia and schizoaffective disorder. <i>Clinical Neurophysiology</i> , 2018, 129, 2315-2324.	0.7	9
22	EEG correlates of induced anxiety in obsessive–compulsive patients: comparison of autobiographical and general anxiety scenarios. <i>Neuropsychiatric Disease and Treatment</i> , 2018, Volume 14, 2165-2174.	1.0	12
23	Theoretical Modeling of Cognitive Dysfunction in Schizophrenia by Means of Errors and Corresponding Brain Networks. <i>Frontiers in Psychology</i> , 2018, 9, 1027.	1.1	17
24	Neonatal immune activation by lipopolysaccharide causes inadequate emotional responses to novel situations but no changes in anxiety or cognitive behavior in Wistar rats. <i>Behavioural Brain Research</i> , 2018, 349, 42-53.	1.2	8
25	Effects of the adipokinetic hormone/red pigment¢concentrating hormone (<sc>AKH</sc>/<sc>RPCH</sc>) family of peptides on <sc>MK</sc>¢induced schizophrenia models. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 589-602.	1.0	4
26	Perception of direct vs. averted gaze in portrait paintings: An fMRI and eye-tracking study. <i>Brain and Cognition</i> , 2018, 125, 88-99.	0.8	18
27	Multi-center machine learning in imaging psychiatry: A meta-model approach. <i>NeuroImage</i> , 2017, 155, 10-24.	2.1	42
28	Endocannabinoid system in sexual motivational processes: Is it a novel therapeutic horizon?. <i>Pharmacological Research</i> , 2017, 115, 200-208.	3.1	26
29	Empathy-Related Responses to Depicted People in Art Works. <i>Frontiers in Psychology</i> , 2017, 8, 228.	1.1	18
30	Why and How. The Future of the Central Questions of Consciousness. <i>Frontiers in Psychology</i> , 2017, 8, 1797.	1.1	8
31	Trans-generational neurochemical modulation of methamphetamine in the adult brain of the Wistar rat. <i>Archives of Toxicology</i> , 2017, 91, 3373-3384.	1.9	18
32	Validity of Quinpirole Sensitization Rat Model of OCD: Linking Evidence from Animal and Clinical Studies. <i>Frontiers in Behavioral Neuroscience</i> , 2016, 10, 209.	1.0	17
33	Sex differences and serotonergic mechanisms in the behavioural effects of psilocin. <i>Behavioural Pharmacology</i> , 2016, 27, 309-320.	0.8	38
34	Neurobiology of the Effects of Psilocybin in Relation to Its Potential Therapeutic Targets. , 2016, , 782-793.		8
35	Altered Neural Correlate of the Self-Agency Experience in First-Episode Schizophrenia-Spectrum Patients: An fMRI Study. <i>Schizophrenia Bulletin</i> , 2016, 42, 916-925.	2.3	26
36	Physical Comorbidities in Depression Co-Occurring with Anxiety: A Cross Sectional Study in the Czech Primary Care System. <i>International Journal of Environmental Research and Public Health</i> , 2015, 12, 15728-15738.	1.2	21

#	ARTICLE	IF	CITATIONS
37	Biochemical, Histopathological and Morphological Profiling of a Rat Model of Early Immune Stimulation: Relation to Psychopathology. PLoS ONE, 2015, 10, e0115439.	1.1	26
38	EEG correlates of a mental arithmetic task in patients with first episode schizophrenia and schizoaffective disorder. Clinical Neurophysiology, 2015, 126, 2090-2098.	0.7	33
39	Sad mood induction has an opposite effect on amygdala response to emotional stimuli in euthymic patients with bipolar disorder and healthy controls. Journal of Psychiatry and Neuroscience, 2015, 40, 134-142.	1.4	19
40	The effect of lacosamide on bone tissue in orchidectomised male albino Wistar rats. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2015, 159, 394-399.	0.2	8
41	A virtual reality task based on animal research Āĉâ,-â€œ spatial learning and memory in patients after the first episode of schizophrenia. Frontiers in Behavioral Neuroscience, 2014, 8, 157.	1.0	34
42	Bridging disparate symptoms of schizophrenia: a triple network dysfunction theory. Frontiers in Behavioral Neuroscience, 2014, 8, 171.	1.0	98
43	Psilocybin â€“ Summary of knowledge and new perspectives. European Neuropsychopharmacology, 2014, 24, 342-356.	0.3	167
44			

#	ARTICLE	IF	CITATIONS
55	Genetic variation in FOXP2 alters grey matter concentrations in schizophrenia patients. <i>Neuroscience Letters</i> , 2011, 493, 131-135.	1.0	34
56	Behavioral, hyperthermic and pharmacokinetic profile of para-methoxymethamphetamine (PMMA) in rats. <i>Pharmacology Biochemistry and Behavior</i> , 2011, 98, 130-139.	1.3	24
57	Effect of tandospirone, a serotonin-1A receptor partial agonist, on information processing and locomotion in dizocilpine-treated rats. <i>Psychopharmacology</i> , 2010, 212, 267-276.	1.5	11
58	Expression of the Hippocampal NMDA Receptor GluN1 Subunit and Its Splicing Isoforms in Schizophrenia: Postmortem Study. <i>Neurochemical Research</i> , 2010, 35, 994-1002.	1.6	44
59	Sex differences in the effects of N,N-diethyllysergamide (LSD) on behavioural activity and prepulse inhibition. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2010, 34, 588-596.	2.5	38
60	The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpine-treated rats. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 873.	1.0	19
61	Medial frontal and dorsal cortical morphometric abnormalities are related to obsessive-compulsive disorder. <i>Neuroscience Letters</i> , 2009, 464, 62-66.	1.0	55
62	Mescaline effects on rat behavior and its time profile in serum and brain tissue after a single subcutaneous dose. <i>Psychopharmacology</i> , 2008, 196, 51-62.	1.5	46
63	Serotonin1A receptors in the pathophysiology of schizophrenia: development of novel cognition-enhancing therapeutics. <i>Advances in Therapy</i> , 2008, 25, 1037-1056.	1.3	43
64	Models of schizophrenia in humans and animals based on inhibition of NMDA receptors. <i>Neuroscience and Biobehavioral Reviews</i> , 2008, 32, 1014-1023.	2.9	294
65	LORETA Functional Imaging in Antipsychotic-Naive and Olanzapine-, Clozapine- and Risperidone-Treated Patients with Schizophrenia. <i>Neuropsychobiology</i> , 2008, 58, 1-10.	0.9	34
66	Effect of Low-Frequency rTMS on Electromagnetic Tomography (LORETA) and Regional Brain Metabolism (PET) in Schizophrenia Patients with Auditory Hallucinations. <i>Neuropsychobiology</i> , 2007, 55, 132-142.	0.9	97
67	The opposite effect of a low and a high dose of serotonin-1A agonist on behavior induced by MK-801. <i>Neuropharmacology</i> , 2007, 52, 1071-1078.	2.0	22
68	18FDG PET in hallucinating and non-hallucinating patients. <i>Neuroendocrinology Letters</i> , 2007, 28, 53-9.	0.2	8
69	An analysis of spontaneous behavior following acute MDMA treatment in male and female rats. <i>Neuroendocrinology Letters</i> , 2007, 28, 781-8.	0.2	12
70	Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia. <i>CNS Drugs</i> , 2006, 20, 389-409.	2.7	385
71	Parallel optimization and genotyping of multiple single-nucleotide polymorphism markers by sample pooling approach using cycling-gradient CE with multiple injections. <i>Electrophoresis</i> , 2006, 27, 3856-3863.	1.3	3
72	Regional brain metabolism as the predictor of performance on the Trail Making Test in schizophrenia. A 18FDG PET covariation study. <i>Neuroendocrinology Letters</i> , 2006, 27, 587-94.	0.2	17

#	ARTICLE	IF	CITATIONS
73	The effect of zotepine, risperidone, clozapine and olanzapine on MK-801-disrupted sensorimotor gating. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 80, 591-596.	1.3	78
74	The effect of tryptophan depletion on the action of haloperidol in MK-801-treated rats. <i>European Journal of Pharmacology</i> , 2004, 502, 109-116.	1.7	10
75	Effects of haloperidol treatment on prolactin response to D -fenfluramine challenge in acute schizophrenia. <i>Psychopharmacology</i> , 1999, 141, 322-325.	1.5	8
76	Prolactin response to d-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. <i>Schizophrenia Research</i> , 1998, 30, 91-99.	1.1	24